{"classes":[{"categories":[{"measurements":[{"comment":"Median and 95% CI was not estimable due to insufficient number of participants with event.","groupId":"OG000","lowerLimit":"NA","upperLimit":"NA","value":"NA"},{"comment":"Median and 95% CI was not estimable due to insufficient number of participants with event.","groupId":"OG001","lowerLimit":"10.9","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"149"},{"groupId":"OG001","value":"74"}],"units":"Participants"}],"title":"PD-L1 Positive Tumors"},{"categories":[{"measurements":[{"comment":"Median and 95% CI was not estimable due to insufficient number of participants with event.","groupId":"OG000","lowerLimit":"11.1","upperLimit":"NA","value":"NA"},{"comment":"Median and 95% CI was not estimable due to insufficient number of participants with event.","groupId":"OG001","lowerLimit":"9.0","upperLimit":"NA","value":"NA"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"62"},{"groupId":"OG001","value":"34"}],"units":"Participants"}],"title":"PD-L1 Negative Tumors"}],"denoms":[{"counts":[{"groupId":"OG000","value":"211"},{"groupId":"OG001","value":"108"}],"units":"Participants"}],"description":"DR: time from first documentation of OR (confirmed CR or PR) to date of first documentation of PD or death due to any cause, whichever occurred first. As per RECIST version 1.1, CR: disappearance of all target and non-target lesions, and sustained for at least 4 weeks. Any pathological lymph nodes (target or non-target) must have reduction in short axis to \\<10 mm. PR: at least 30%\\< in sum of longest dimensions of target lesions taking as reference baseline sum longest dimensions. PD: defined as at least a 20% \\> in sum of diameters of target lesions, taking as reference the smallest sum on study (this included baseline sum if that is smallest on study). In addition to relative increase of 20%, sum must have also demonstrated an absolute increase of at least 5 mm. Appearance of one or more new lesions was also considered progression.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants with aRCC received avelumab 10 mg/kg, IV at Q2W in a 6-week cycle plus axitinib 5 mg, orally BID. Each treatment cycle was 42 days.","id":"OG000","title":"Avelumab + Axitinib"},{"description":"Participants with aRCC received sunitinib 50 mg orally, QD on a schedule of 4 weeks on treatment followed by 2 weeks off treatment (schedule 4/2 in 6-week cycles). Each treatment cycle was of 42 days.","id":"OG001","title":"Sunitinib"}],"paramType":"MEDIAN","populationDescription":"Biomarker positive/negative subset in FAS included participants who had at least one biomarker baseline assessment. Here \"Number of Participants Analyzed\" signifies participants evaluable for this outcome measure. \"Number Analyzed\" signifies number of participants evaluable for the specified rows.","reportingStatus":"POSTED","timeFrame":"From documentation of OR until date of first documentation of PD or death due to any cause, whichever occurred first (maximum up to approximately 26 months)","title":"DR in PD-L1 Biomarker-Positive and PD-L1 Biomarker-Negative Subgroups","type":"SECONDARY","unitOfMeasure":"Months"}